帕金森病是一种神经系统退行性疾病,给患者的生活带来了重大影响。而近年来,人工智能技术的发展为帕金森病的诊治提供了新的机会和挑战。本文将从帕金森病的诊断、监测和评估、治疗方法三个方面切入,对不同人工智能技术在帕金森病诊治中的应用进行总结,了解其原理、分析其应用现状及存在的问题,并对未来的发展进行展望。Parkinson’s disease is a neurodegenerative disease that brings significant impact on patients’ lives. And in recent years, the development of artificial intelligence technology has provided new opportunities and challenges for the diagnosis and treatment of Parkinson’s disease. In this paper, we will summarize the application of various AI technologies in the diagnosis and treatment of Parkinson’s disease from three aspects, namely, diagnosis, monitoring and evaluation, and treatment methods, in order to understand the principles, analyze the current status of their application and the existing problems, and to look forward to the future development.
目的评价新型抗凝药(NOACs)对亚洲心房颤动(房颤,AF)患者脑卒中的预防效果与安全性。方法制定相应的检索策略,检索中国生物医学文献数据库、中国知网、维普网、万方数据、PubMed、Embase、The Cochrane Library、Web of Science电子数据库,纳入NOACs和华法林对亚洲房颤患者治疗比较的随机对照试验,提取文献相关信息,并评价纳入文献的质量。结果总共纳入24篇文献,其中包括10785例受试者。Meta分析表明,与华法林比较,NOACs能降低亚洲房颤患者脑卒中(RR=0.63,95%CI:0.52~0.76,P<0.00001)、非神经系统性血栓栓塞(RR=0.46,95%CI:0.31~0.68,P=0.0001)及大出血(RR=0.61,95%CI:0.51~0.72,P<0.00001)的发生。结论采用NOACs治疗亚洲房颤患者脑卒中、非神经系统性血栓栓塞及大出血发生率低于华法林,NOACs用于治疗亚洲房颤患者具有良好的有效性与安全性。
